MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis

NASDAQ:MDXG • US6024961012

4.89 USD
-0.05 (-1.01%)
At close: Feb 27, 2026
4.9 USD
+0.01 (+0.2%)
After Hours: 2/27/2026, 8:17:42 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

MDXG gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. MDXG has an excellent financial health rating, but there are some minor concerns on its profitability. MDXG is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • MDXG had positive earnings in the past year.
  • MDXG had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: MDXG reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: MDXG reported negative operating cash flow in multiple years.
MDXG Yearly Net Income VS EBIT VS OCF VS FCFMDXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 12.80%, MDXG belongs to the top of the industry, outperforming 94.83% of the companies in the same industry.
  • MDXG has a better Return On Equity (17.09%) than 95.21% of its industry peers.
  • MDXG has a better Return On Invested Capital (15.15%) than 95.98% of its industry peers.
Industry RankSector Rank
ROA 12.8%
ROE 17.09%
ROIC 15.15%
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
MDXG Yearly ROA, ROE, ROICMDXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

  • MDXG has a better Profit Margin (10.38%) than 90.80% of its industry peers.
  • Looking at the Operating Margin, with a value of 13.73%, MDXG belongs to the top of the industry, outperforming 92.34% of the companies in the same industry.
  • In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
  • With an excellent Gross Margin value of 81.99%, MDXG belongs to the best of the industry, outperforming 86.21% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
Industry RankSector Rank
OM 13.73%
PM (TTM) 10.38%
GM 81.99%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
MDXG Yearly Profit, Operating, Gross MarginsMDXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • MDXG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • There is no outstanding debt for MDXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MDXG Yearly Shares OutstandingMDXG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
MDXG Yearly Total Debt VS Total AssetsMDXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • MDXG has an Altman-Z score of 7.71. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of MDXG (7.71) is better than 78.35% of its industry peers.
  • MDXG has a debt to FCF ratio of 0.27. This is a very positive value and a sign of high solvency as it would only need 0.27 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.27, MDXG belongs to the top of the industry, outperforming 95.40% of the companies in the same industry.
  • MDXG has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
  • MDXG's Debt to Equity ratio of 0.07 is on the low side compared to the rest of the industry. MDXG is outperformed by 60.54% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.27
Altman-Z 7.71
ROIC/WACC1.79
WACC8.48%
MDXG Yearly LT Debt VS Equity VS FCFMDXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 4.41 indicates that MDXG has no problem at all paying its short term obligations.
  • The Current ratio of MDXG (4.41) is comparable to the rest of the industry.
  • MDXG has a Quick Ratio of 3.95. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
  • MDXG has a Quick ratio (3.95) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.41
Quick Ratio 3.95
MDXG Yearly Current Assets VS Current LiabilitesMDXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • MDXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.17%, which is quite impressive.
EPS 1Y (TTM)55.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%180%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%27.12%

3.2 Future

  • Based on estimates for the next years, MDXG will show a very negative growth in Earnings Per Share. The EPS will decrease by -26.24% on average per year.
  • The Revenue is expected to grow by 13.71% on average over the next years. This is quite good.
EPS Next Y-75.07%
EPS Next 2Y-26.24%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-2.78%
Revenue Next 2Y5.85%
Revenue Next 3Y13.58%
Revenue Next 5Y13.71%

3.3 Evolution

MDXG Yearly Revenue VS EstimatesMDXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
MDXG Yearly EPS VS EstimatesMDXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 10.87, the valuation of MDXG can be described as reasonable.
  • Compared to the rest of the industry, the Price/Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 97.32% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.07, MDXG is valued rather cheaply.
  • A Price/Forward Earnings ratio of 43.58 indicates a quite expensive valuation of MDXG.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 90.80% of the companies listed in the same industry.
  • MDXG's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.05.
Industry RankSector Rank
PE 10.87
Fwd PE 43.58
MDXG Price Earnings VS Forward Price EarningsMDXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • MDXG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDXG is cheaper than 97.51% of the companies in the same industry.
  • MDXG's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MDXG is cheaper than 97.89% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.84
EV/EBITDA 8.74
MDXG Per share dataMDXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • The decent profitability rating of MDXG may justify a higher PE ratio.
  • A cheap valuation may be justified as MDXG's earnings are expected to decrease with -26.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.24%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for MDXG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MIMEDX GROUP INC

NASDAQ:MDXG (2/27/2026, 8:17:42 PM)

After market: 4.9 +0.01 (+0.2%)

4.89

-0.05 (-1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-28
Inst Owners71.94%
Inst Owner Change0.19%
Ins Owners1.79%
Ins Owner Change-0.23%
Market Cap724.21M
Revenue(TTM)N/A
Net Income(TTM)40.83M
Analysts81.82
Price Target9.86 (101.64%)
Short Float %4.91%
Short Ratio7.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)-20.76%
PT rev (3m)-20.76%
EPS NQ rev (1m)-1.13%
EPS NQ rev (3m)-30.95%
EPS NY rev (1m)-21.43%
EPS NY rev (3m)-22.35%
Revenue NQ rev (1m)-0.15%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.11%
Valuation
Industry RankSector Rank
PE 10.87
Fwd PE 43.58
P/S 1.84
P/FCF 10.84
P/OCF 10.68
P/B 3.03
P/tB 3.48
EV/EBITDA 8.74
EPS(TTM)0.45
EY9.2%
EPS(NY)0.11
Fwd EY2.29%
FCF(TTM)0.45
FCFY9.23%
OCF(TTM)0.46
OCFY9.37%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Graham Number4.04
Profitability
Industry RankSector Rank
ROA 12.8%
ROE 17.09%
ROCE 20.67%
ROIC 15.15%
ROICexc 33.2%
ROICexgc 44.66%
OM 13.73%
PM (TTM) 10.38%
GM 81.99%
FCFM 16.98%
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 0.27
Debt/EBITDA 0.25
Cap/Depr 6.96%
Cap/Sales 0.26%
Interest Coverage 36.69
Cash Conversion 98.8%
Profit Quality 163.64%
Current Ratio 4.41
Quick Ratio 3.95
Altman-Z 7.71
F-Score6
WACC8.48%
ROIC/WACC1.79
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%180%
EPS Next Y-75.07%
EPS Next 2Y-26.24%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%27.12%
Revenue Next Year-2.78%
Revenue Next 2Y5.85%
Revenue Next 3Y13.58%
Revenue Next 5Y13.71%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year63.93%
EBIT Next 3Y14.69%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A

MIMEDX GROUP INC / MDXG FAQ

Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?

ChartMill assigns a fundamental rating of 6 / 10 to MDXG.


Can you provide the valuation status for MIMEDX GROUP INC?

ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.


What is the profitability of MDXG stock?

MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.


What is the financial health of MIMEDX GROUP INC (MDXG) stock?

The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.


What is the earnings growth outlook for MIMEDX GROUP INC?

The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to decline by -75.07% in the next year.